标准化流式细胞术用于B细胞急性淋巴细胞白血病高灵敏度MRD检测
欧洲流式(EuroFlow)通过5轮多中心设计-测试-评估-重新设计,建立全标准化8色抗体组合与实验室流程,在319例初诊B细胞前体急性淋巴细胞白血病(BCP-ALL)患者中使99%可区分正常与恶性BCP细胞;
要点
- EuroFlow全标准化8色流式方案在99%的BCP-ALL患者中可区分正常与恶性BCP细胞。
- 经高通量测序及盲法复核后,总一致率达98%(MRD<0.01%样本为97%)。
核心结论
- 全标准化EuroFlow BCP-ALL MRD策略在>98%的患者中适用,若评估足够细胞(>4×10^6,最好更多),灵敏度至少与RQ-PCR相当(≤10^-5)。
研究设计与样本
- 全标准化EuroFlow 8色抗体组合及实验室流程经5轮多中心设计-测试-评估-重新设计,共纳入319例初诊BCP-ALL患者。
- 选用2个8色抗体管,并在178例BCP-ALL患者的377份骨髓随访样本中采用新的红细胞批量裂解方案进行测试。
主要发现
- 2个8色抗体管在99%的研究患者中可区分正常与恶性BCP细胞。
- 与RQ-PCR的MRD数据比较,一致样本百分比与采集细胞数呈明显正相关。
- 多数不一致经抗原受体 rearrangement 高通量测序及盲法多中心流式数据复核后得到澄清,总一致率达98%(MRD<0.01%样本为97%)。
关键数值与推荐
- 灵敏度≤10^-5,与基于抗原受体 rearrangement 的RQ-PCR MRD检测相当。
- 采集细胞数>4×10^6(最好更多)时评估。
- 总一致率98%,MRD<0.01%样本一致率97%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A fully-standardized EuroFlow 8-color antibody panel and laboratory procedure was stepwise designed to measure minimal residual disease (MRD) in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) patients with a sensitivity of ≤10-5, comparable to real-time quantitative polymerase chain reaction (RQ-PCR)-based MRD detection via antigen-receptor rearrangements. Leukocyte markers and the corresponding antibodies and fluorochromes were selected based on their contribution in separating BCP-ALL cells from normal/regenerating BCP cells in multidimensional principal component analyses. After 5 multicenter design-test-evaluate-redesign phases with a total of 319 BCP-ALL patients at diagnosis, two 8-color antibody tubes were selected, which allowed separation between normal and malignant BCP cells in 99% of studied patients. These 2 tubes were tested with a new erythrocyte bulk-lysis protocol allowing acquisition of high cell numbers in 377 bone marrow follow-up samples of 178 BCP-ALL patients. Comparison with RQ-PCR-based MRD data showed a clear positive relation between the percentage concordant cases and the number of cells acquired. For those samples with >4 million cells acquired, concordant results were obtained in 93% of samples. Most discordances were clarified upon high-throughput sequencing of antigen-receptor rearrangements and blind multicenter reanalysis of flow cytometric data, resulting in an unprecedented concordance of 98% (97% for samples with MRD < 0.01%). In conclusion, the fully standardized EuroFlow BCP-ALL MRD strategy is applicable in >98% of patients with sensitivities at least similar to RQ-PCR (≤10-5), if sufficient cells (>4 × 106, preferably more) are evaluated.
引用
- Theunissen P, Mejstrikova E, Sedek L, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 2016. PMID: 27903527. doi:10.1182/blood-2016-07-726307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。